Naxitamab plus standard therapy for newly diagnosed high-risk neuroblastoma
Treatments studied
Part of Cancer clinical trials.
This study tests adding two medications (naxitamab and GM-CSF) to standard chemotherapy for children and young adults with newly diagnosed high-risk neuroblastoma, a cancer of nerve cells. The goal is to help the body's immune system fight the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 1 and 21 years old
- Newly diagnosed with high-risk neuroblastoma confirmed by pathology or bone marrow testing
- Meets specific stage and age criteria for high-risk disease (based on INRG staging)
- Enrolled within 6 weeks of diagnosis, with no prior chemotherapy (except up to 1 cycle or emergency radiation)
- Adequate organ function: kidneys, liver, and heart working well enough for treatment
- Not pregnant, not breastfeeding, and able to use contraception if sexually active
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding the antibody dinutuximab-beta to standard chemotherapy for children and young adults with newly diagnosed high-risk neuroblastoma. The goal is to see if this combination helps the immune system fight the cancer better.
This Phase 1 trial tests a combination of dinutuximab beta (an immunotherapy) and chemotherapy in children with high-risk neuroblastoma that did not respond to standard treatment or has come back or progressed. It aims to see how well the treatment works and how safely it can be given in this situation.
This Phase 2 trial tests whether adding a drug called naxitamab to standard early (frontline) treatment improves outcomes for children with high-risk neuroblastoma. It may help by helping the immune system better target the cancer during initial induction therapy.
This trial is for children with high-risk neuroblastoma, a type of nerve cell cancer. It tests adding a new medicine called Naxitamb to standard induction therapy to see if it works better. High-risk means the cancer is advanced or has certain aggressive features.
This trial tests a targeted antibody called naxitamab (hu3F8) for children with high-risk neuroblastoma that has come back or is hard to treat. It aims to see if this therapy can help shrink or control the cancer with an acceptable safety profile.
This trial tests a combination of naxitamab, GM-CSF, and isotretinoin as maintenance therapy for children with high-risk neuroblastoma who have achieved their first complete response after initial treatment. The goal is to help keep the cancer from coming back.
Hear when a new High-Risk Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.